Clinical Trial Update: Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing secukinumab to adalimumab in psoriatic arthritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)
• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2021-01-27